Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01368484
Other study ID # IVI MUR 005-2009
Secondary ID
Status Completed
Phase N/A
First received June 7, 2011
Last updated June 7, 2011
Start date December 2009
Est. completion date March 2011

Study information

Verified date June 2011
Source Instituto Valenciano de Infertilidad, IVI VALENCIA
Contact n/a
Is FDA regulated No
Health authority Spain: Ministry of Health
Study type Interventional

Clinical Trial Summary

The aim of this study is evaluated the effect of dietetic supplementation with DHA on human sperm quality, antioxidant capacity and sperm DNA damage.


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date March 2011
Est. primary completion date December 2010
Accepts healthy volunteers No
Gender Male
Age group N/A and older
Eligibility Inclusion Criteria:

- Diagnosis of male factor.

Exclusion Criteria:

- Metabolic and genetic diseases.

- Oncological patients.

- Patients with anticoagulants treatment.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Sunflower oil
1500 mg sunflower/day for 10 weeks
Docosahexanoic acid
1500mg/day for 10 weeks

Locations

Country Name City State
Spain Instituto Valenciano de infertilidad Murcia

Sponsors (2)

Lead Sponsor Collaborator
Instituto Valenciano de Infertilidad, IVI VALENCIA University of Barcelona

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary sperm concentration million of spermatozoa per milimitre 5 weeks No
Primary Sperm motility Percentage of motile sperm. 5 weeks No
Primary Sperm morphology Percentage of sperm with normal morphology 5 weeks No
Primary Total capacity antioxidant Total antioxidant capacity (TAC)is a colorimetric assay that measure the combined antioxidant activities of all its non enzymatic constituents in seminal plasma. 5 weeks No
Primary Sperm DNA damage. DNA fragmentation analysis was evaluated by TUNEL test and measured by flow cytometry 5 weeks No
Primary Fatty acids measure. Fatty acid analysis in seminal plasma and spermatozoa were evaluated by gas chromatography.The percentage of each fatty acid class was expressed as percentage of total fatty acids. 5 weeks No
Secondary Sperm in ejaculate Million of spermatozoa in eyaculate. 5 weeks No
Secondary Volume of ejaculate. Eyaculated milliliters. 5 weeks No
Secondary Sperm viability Porcentage of sperm whitout membrane damage 5 weeks No
See also
  Status Clinical Trial Phase
Recruiting NCT06172504 - Ejaculation Frequency and Semen Parameters
Completed NCT02422108 - TNFSF11 Inhibition and Fertility: a Prospective Study Phase 2
Withdrawn NCT02431000 - Male Fertility and Sperm Cryopreservation
Withdrawn NCT02869425 - To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS Phase 3
Recruiting NCT06243926 - Sperm Selection by Rheotaxis and Thermotaxis in In-Situ Handmade Microfluidics of Fluidic Walls in the Same ICSI Plate
Completed NCT03153436 - The Effect of In-vitro Myoinositol Supplementation of Human Sperm on the Outcome of Cryopreservation Phase 1/Phase 2
Recruiting NCT05508217 - Impact of Telomere Biology and Sperm DNA Fragmentation on Embryonic Development